These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 14585058)

  • 1. Fenretinide: a prototype cancer prevention drug.
    Malone W; Perloff M; Crowell J; Sigman C; Higley H
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1829-42. PubMed ID: 14585058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
    Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
    Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
    [No Abstract]   [Full Text] [Related]  

  • 3. Fenretinide and cancer prevention.
    Torrisi R; Decensi A
    Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.
    Pienta KJ; Esper PS; Zwas F; Krzeminski R; Flaherty LE
    Am J Clin Oncol; 1997 Feb; 20(1):36-9. PubMed ID: 9020285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.
    Slawin K; Kadmon D; Park SH; Scardino PT; Anzano M; Sporn MB; Thompson TC
    Cancer Res; 1993 Oct; 53(19):4461-5. PubMed ID: 8402613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer prevention trials using retinoids.
    Decensi A; Serrano D; Bonanni B; Cazzaniga M; Guerrieri-Gonzaga A
    J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):19-30. PubMed ID: 14587861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Hydroxyphenylretinamide in the chemoprevention of cancer.
    Naik HR; Kalemkerian G; Pienta KJ
    Adv Pharmacol; 1995; 33():315-47. PubMed ID: 7495674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenretinide and its relation to cancer.
    Ulukaya E; Wood EJ
    Cancer Treat Rev; 1999 Aug; 25(4):229-35. PubMed ID: 10448131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic retinoid fenretinide in breast cancer chemoprevention.
    Bonanni B; Lazzeroni M; Veronesi U
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
    Mariani L; Formelli F; De Palo G; Manzari A; Camerini T; Campa T; Di Mauro MG; Crippa A; Delle Grottaglie M; Del Vecchio M; Marubini E; Costa A; Veronesi U
    Tumori; 1996; 82(5):444-9. PubMed ID: 9063520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies.
    Sogno I; Venè R; Ferrari N; De Censi A; Imperatori A; Noonan DM; Tosetti F; Albini A
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):2-14. PubMed ID: 20034809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [-Results of ongoing breast cancer prevention studies-].
    Jungi WF
    Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
    [No Abstract]   [Full Text] [Related]  

  • 17. Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials.
    Veronesi U; Decensi A
    J Natl Cancer Inst; 2001 Apr; 93(7):486-8. PubMed ID: 11287432
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
    Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
    Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland.
    Green A; Shilkaitis A; Christov K
    Carcinogenesis; 1999 Aug; 20(8):1535-40. PubMed ID: 10426803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.